Send to

Choose Destination

See 1 citation found by title matching your search:

Pediatr Infect Dis J. 2018 Sep;37(9):e233-e240. doi: 10.1097/INF.0000000000002124.

Antibody Persistence up to 3 Years After Primary Immunization With Inactivated Japanese Encephalitis Vaccine IXIARO in Philippine Children and Effect of a Booster Dose.

Author information

From the Valneva Austria GmbH, Vienna, Austria.
Department of Health, Research Institute for Tropical Medicine, Manila, Philippines.
Department of Pediatrics.
College of Medicine, University of the Philippines, Manila, Philippines.
Section of Infectious and Tropical Diseases, Department of Pediatrics, Philippine General Hospital, Manila, Philippines.
Department of Health, Research Institute for Tropical Medicine, Muntinlupa, Philippines.
Center for Public Health, Medical University of Vienna, Austria.



An inactivated Vero cell culture derived Japanese encephalitis virus vaccine (IXIARO) requires a booster dose 1 year after primary schedule for long-term antibody persistence in adults. The aim of this study is to evaluate immunogenicity and safety of a booster dose in children 2 months to <18 years of age.


This is a randomized, controlled open-label study in the Philippines. Three hundred children vaccinated with IXIARO in a previous trial were randomized 1:1 to receive either no booster or a booster 12 months after initiation of the primary series. Neutralizing antibody titers were assessed before and after the booster and up to 3 years after primary series. Safety endpoints included the rate of subjects with solicited adverse events (AEs), unsolicited AEs and serious AEs within 1 month after the booster.


Geometric mean titer declined by 1 year after the primary series, but titers remained above the established protective threshold in 85%-100% of children depending on age group. The booster led to a pronounced increase in geometric mean titer and 100% seroprotection rate in all age groups. The booster was well tolerated, with AE rates lower compared with the primary series. Most AEs were mild.


A booster dose of IXIARO administered 12 months after the primary immunization was well tolerated and highly immunogenic.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center